
Non–Small-Cell Lung Cancer Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Dr Lisberg discusses when to use checkpoint inhibitor therapy for targetable mutations in NSCLC, a recap of his presentation at the 2020 Personalized Therapies in Thoracic Oncology meeting.
View MoreSolange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with…
View MoreSolange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
View MoreDavid Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
View MoreYasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.
View MoreMartin J. Edelman, MD, discusses how the treatment landscape for advanced NSCLC has evolved in recent years.
View MoreJessica Donington, MD, discusses the role of surgery in managing patients with locally advanced NSCLC.
View MoreDr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.
View MoreEdward B. Garon, MD, MS, discusses second-line therapies for the treatment of patients with NSCLC.
View More